Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes.
about
Ability of two commercially available assays (Abbott RealTime HIV-1 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2.0) to quantify low HIV-1 RNA Levels (<1,000 copies/milliliter): comparison with clinical samples and NIBSC working reagent forComparative evaluation of the performance of the Abbott RealTime HIV-1 assay for measurement of HIV-1 plasma viral load on genetically diverse samples from GreeceCobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.Use of reverse-transcriptase-based HIV-1 viral load assessment to confirm low viral loads in newly diagnosed patients in Switzerland.Systematic review of the performance of HIV viral load technologies on plasma samples.An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study.Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays.Molecular virology in transfusion medicine laboratory.Clinical and resistance consequences of misquantification of plasma and cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype G-infected patient.Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration.Risk Minimization Measures for Blood Screening HIV-1 Nucleic Acid Amplification Technique Assays in Germany.Current challenges to viral load testing in the context of emerging genetic diversity of HIV-1.Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification.Upgraded Cobas Ampliprep-Cobas TaqMan version 2.0 HIV-1 RNA quantification assay versus first version: correction of underestimations.Significant impact of non-B HIV-1 variants genetic diversity in Gabon on plasma HIV-1 RNA quantitation.A cluster of human immunodeficiency virus Type 1 recombinant form escaping detection by commercial genomic amplification assays.
P2860
Q33703537-B17AEFD2-B752-44D1-9CF6-1808B670A019Q34547246-1856F5DD-EAA6-4183-B099-971B23871161Q34983777-27B4708F-0D88-43AF-97BD-013BF308AD07Q35093899-806A4BC4-0200-4DA1-8C08-00F9A1C94F0DQ35099443-60EFEA2E-A157-4967-8708-B5C67D96E41DQ35273824-9504000F-DA1D-4DD7-ABE7-6F569B0FEAC1Q35356381-C0734B3B-2F3C-4072-93E6-328E28164A0FQ36766449-272A3E02-E902-41CF-B6DD-8DFC8A663F1AQ37410496-B9D375A8-78EB-4D2E-A538-9BD66A1C8A33Q37546182-A58ACB25-6348-4104-A88C-705B46C85724Q37630304-D29F3277-B7A2-407E-942F-EA15D25CB348Q38088726-B4584DB1-E9C2-4204-966B-E997281EA072Q38417936-DBB2DBDC-E479-428A-82B5-01B056D73861Q41844856-4F93BE7A-5486-4F3B-9A84-13EBDF7D8E32Q42262384-5655F421-1966-4FCA-947B-1EF53D76DC0CQ45371172-DE4CC8DF-9BF8-41FB-856B-825B72C7415A
P2860
Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Impact of discrepancies betwee ...... type 1 group M non-B subtypes.
@en
Impact of discrepancies betwee ...... type 1 group M non-B subtypes.
@nl
type
label
Impact of discrepancies betwee ...... type 1 group M non-B subtypes.
@en
Impact of discrepancies betwee ...... type 1 group M non-B subtypes.
@nl
prefLabel
Impact of discrepancies betwee ...... type 1 group M non-B subtypes.
@en
Impact of discrepancies betwee ...... type 1 group M non-B subtypes.
@nl
P2093
P2860
P356
P1476
Impact of discrepancies betwee ...... type 1 group M non-B subtypes.
@en
P2093
A G Marcelin
M Bonmarchand
Z Ait-Arkoub
P2860
P304
P356
10.1128/JCM.02134-08
P407
P577
2009-03-18T00:00:00Z